Lapp T, Maier P, Birnbaum F, Schlunck G, Reinhard T
Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Deutschland,
Ophthalmologe. 2014 Mar;111(3):270-82. doi: 10.1007/s00347-013-3016-6.
In order to prevent rejection of an allogeneic corneal transplant after perforating (high risk) keratoplasty, active agents from different classes of pharmacological substances are used, as with solid organ transplantation. In addition to glucocorticoids, antiproliferative agents, small molecule inhibitors and antibodies, those belonging to the group of macrolides with their many derivatives represent an interesting class of substances in this context. As a supplement to cyclosporin A (CSA) the most successful macrolide in transplantation medicine, animal experiments are currently being carried out to test newer macrolide derivatives, such as sanglifehrin A (SFA). This overview describes the classes of drugs and modes of action of currently administered standard medications in the clinical routine and new developments are presented.
为防止穿透性（高风险）角膜移植术后发生同种异体角膜移植排斥反应，与实体器官移植一样，使用了不同类别的药理活性物质。除糖皮质激素、抗增殖剂、小分子抑制剂和抗体外，大环内酯类及其众多衍生物在这方面是一类有趣的物质。作为移植医学中最成功的大环内酯类药物环孢素A（CSA）的补充，目前正在进行动物实验以测试新型大环内酯类衍生物，如桑吉霉素A（SFA）。本综述描述了临床常规中目前使用的标准药物的类别和作用方式，并介绍了新进展。
